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Melanoma antigen (MAGE)-encoding genes are expressed in various tumour types via demethylation of their promoter CpG islands,
which are silent in all non-neoplastic tissues except for the testis and placenta. The clinicopathological significance of demethylation of
MAGE genes in gastric carcinoma is not known. We investigated the promoter methylation status of MAGE-A1 and -A3 in 10 gastric
cancer cell lines and in surgical specimens from 84 gastric cancer patients by methylation-specific PCR (MSP). Expression of MAGE-A1
and -A3 in the 10 gastric cancer cell lines was also investigated by RT–PCR. Any correlation between the methylation status of the
MAGE promoters and clinicopathological characteristics of the gastric cancer patients was then assessed. Eight of the 10 gastric cancer
cell lines showed demethylation of both MAGE-A1 and -A3, and the remaining two cell lines did either of MAGE-A1 or -A3. Expression
of MAGE-A1 and -A3 was confirmed in seven and nine of the 10 gastric cancer cell lines, respectively. The MAGE-A1 and -A3
promoters were demethylated in 29% (25 out of 84) and 66% (56 out of 84) of the gastric tumour specimens, respectively.
Demethylation of both MAGE-A1 and -A3 promoters (n¼22) was found more frequently in gastric cancer patients in advanced
clinical stages (P¼0.0035), and these patients also exhibited a higher incidence of lymph node metastasis (P¼0.0007) compared to
those patients without demethylation (n¼25). Furthermore, demethylation patients tended to have a worse prognosis, although this
difference was not statistically significant (P¼0.183). Demethylation of MAGE-A1 and -A3 occurs during progressive stages of gastric
cancer, and may be associated with aggressive biological behaviour of gastric cancer.
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Epigenetic alterations, including hypermethylation of promoter
CpG islands and histone deacetylation of tumour suppressor and
tumour-related genes (Choi et al, 2001; Jones and Takai, 2001; Kim
et al, 2001; Goodman and Watson, 2002; Jones and Baylin, 2002) as
well as global DNA hypomethylation (Eden et al, 2003; Gaudet et al,
2003; Lengauer, 2003), have been recognised as important
contributors to carcinogenesis in humans. Global DNA hypo-
methylation has been observed in carcinomas of the breast, liver,
and colon, and is considered to occur in the early stages of tumour
development (Goelz et al, 1985; Cravo et al, 1996; Narayan et al,
1998; Lin et al, 2001; Bariol et al, 2003). However, little is known
about promoter hypomethylation of specific genes such as
oncogenes and growth-related genes, with the exception of the
association between demethylation and increased expression of
c-abl,c - myc, Ha-ras, and raf (Cheah et al, 1984; Weitzman et al,
1989; Sharrad et al, 1992; Counts and Goodman, 1994).
Human melanoma cells express antigens that are recognised by
cytolytic T lymphocytes derived from the blood of tumour-bearing
patients or from tumour-infiltrating lymphocytes (Boon et al,
1994). A number of such antigens are encoded by genes of the
MAGE family (Van der Bruggen et al, 1991; Lucas et al, 2000). A
total of 19 MAGE genes are located on chromosome X (Lucas
et al, 2000), and are expressed in other tumours, including
gastric cancer, in addition to melanoma (Van der Bruggen et al,
1991; Brasseur et al, 1992; Chambost et al, 1993; Inoue et al,
1995a,b; Gotoh et al, 1998; Takahashi et al, 1998). Although the
functions of the various MAGE proteins remain to be elucidated,
MAGE gene expression is known to be activated by promoter
demethylation in a similar manner as the oncogenes and growth-
related genes described above (De Smet et al, 1996). These genes
are silent in normal tissues except for the testis and placenta (De
Plaen et al, 1994; De Smet et al., 1994), and may be targets for
future cancer immunotherapies (Marchand et al, 1999; Jang et al,
2001).
In the present study, we investigated the promoter methylation
status of MAGE-A1 and -A3, which were the most frequent targets
for immunotherapy, in gastric cancers, and analysed the correla-
tion between the MAGE-A1 and -A3 methylation status and
clinicopathological parameters of gastric cancer patients, including
event-free survival.
MATERIALS AND METHODS
Gastric cancer cell lines
We have investigated 10 gastric cancer cell lines with variable
histologies that were cultured under appropriate conditions in our
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ylaboratory: MKN1, an adenosquamous cell carcinoma; MKN7, a
well-differentiated adenocarcinoma; MKN28 and MKN74, moder-
ately differentiated adenocarcinomas; MKN45 and KWS-I, poorly
differentiated adenocarcinoma; KATO-III, a signet-ring cell
carcinoma; TSG11, a hepatoid carcinoma; and ECC10 and
ECC12, endocrine cell carcinomas.
Primary gastric cancers
In total, 84 pairs of cancerous and noncancerous gastric tissues (51
differentiated and 31 undifferentiated carcinomas; 25 early-stage
carcinomas that demonstrated a depth of invasion limited to the
submucosa and 57 advanced stage carcinomas) were surgically
obtained from 84 gastric cancer patients. These tissues were
immediately frozen and stored at  801C until analysis. All patients
received a median of 36.7 months of follow-up care (range, 1–77
months). Signed informed consent was obtained from every
patient to allow the use of biological materials for biological
studies.
DNA extraction
DNA was extracted from 10 gastric carcinoma cell lines and
84 primary gastric cancers and their corresponding
noncancerous gastric tissues with SepaGene (Sanko-Junyaku,
Tokyo, Japan).
RNA extraction
Total RNA was isolated from 10 gastric carcinoma cell lines with
the TRIZOL reagent (Gibco BRL, Life Technologies, Gaithersburg,
MD, USA).
Bisulphite modification and methylation-specific
polymerase chain reaction (MSP)
Treatment of DNA samples with sodium bisulphite converts all
unmethylated cytosines to uracils and does not affect methylated
cytosines. Briefly, 2mg of genomic DNA were denatured with
sodium hydroxide and modified by sodium bisulphite. The
samples were then purified using Wizard DNA purification resin
(Promega, Madison, WI, USA), treated with NaOH, recovered in
ethanol, and resuspended in 30ml of distilled water. Amplification
was achieved in a 20ml reaction volume containing 2mlo f
GeneAmp PCR Gold Buffer (PE Applied Biosystems, Foster City,
CA, USA), 1.0mM MgCl2,1ml each primer, 0.2mM dNTPs, and 1U
Taq polymerase (AmpliTaq Gold DNA Polymerase, PE Applied
Biosystems). After heating at 941C for 10min, polymerase chain
reaction (PCR) was performed in a thermal cycler (GeneAmp 2400,
PE Applied Biosystems) for 35 cycles, each of which consisted of
denaturation at 941C for 30s, annealing at 541C for 60s, and
extension at 721C for 60s, followed by a final 7-min extension at
721C. A positive control (Sss-I methylase-treated DNA) and
negative control (distilled water without DNA) were included for
each amplification. The PCR products were separated on a 6%
nondenaturing polyacrylamide gel. The following primer sets were
used: MG1M forward (50-ATT TAG GTA GGA TTC GGT TTT C-30)
and MG1M reverse (50-AAA CTA AAA CGT CTT CCC GCG-30) for
the methylated MAGE-A1 sequence; MG1U forward (50-ATT TAG
GTA GGA TTT GGT TTT T-30) and MG1U reverse (50-AAA CTA
AAA CAT CTT CCC ACA-30) for the MAGE-A1 unmethylated
sequence; MG3M forward (50-CGT TTT GAG TAA CGA GCG AC-
30) and MG3M reverse (50-ACT AAA ACG ACG AAA ATC GAC G-
30) for the MAGE-A3 methylated sequence; MG3U forward (50-TGT
TTT GAG TAA TGA GTG AT-30) and MG3U reverse (50-ACT AAA
ACA ACA AAA ATC AAC A-30) for the MAGE-A3 unmethylated
sequence. Methylated and unmethylated PCR products of MAGE-
A1 and -A3 in gastric cancer cell lines were sequenced. The PCR
products were purified using QIA Quick PCR Purification Kit
(QIAGEN, Tokyo). The purified PCR products were sequenced
with the BigDye Terminator Cycle Sequencing Ready Reaction Kit
(PE Applied Bioststems). Gel electrophotesis, data collection, and
analysis were carried out with a Genetic Analyser (model 310, PE
Applied Biosystems).
Reverse transcription-PCR (RT–PCR)
Isolated RNA was reverse-transcribed and amplified using a ONE-
STEP RT–PCR System (Gibco BRL). Primer sequences used were:
MG1 forward (50-TGT GGG CAG GAG CTG GGC AA-30) and MG1
reverse (50-GCC GAA GGA ACC TGA CCC AG-30) for MAGE-A1;
MG3 forward (50-AAG CCG GCC CAG GCT CGG T-30) and MG3
reverse (50-GCT GGG CAA TGG AGA CCC AC-30) for MAGE-A3;
b-actin forward (50-AAA TCT GGC ACC ACA CCT T-30) and b-
actin reverse (50-AGC ACT GTG TTG GCG TAG AG-30) for b-actin.
Reverse transcription–PCR products were separated on 3%
agarose gels.
Preparation of positive control
Sss-I methylase (New England BioLabs, Inc.,. Beverly, MA, USA)
was used to methylate 100mg of peripheral blood DNA, which was
modified by sodium bisulphite as described above.
Statistical analysis
Statistical comparisons were performed using Fisher’s exact test.
A Po0.05 was considered significant. Survival analysis was
performed using a Kaplan–Meier curve with log rank test.
RESULTS
Demethylation and expression of MAGE-A1 and -A3 in
gastric cancer cell lines
The demethylation status of MAGE-A1 and -A3 was determined in
nine of the 10 cell lines; it was not determined for MAGE-A1 in line
MKN45 or for MAGE-A3 in line KWS-I (Figure 1). Both the
methylated and demethylated alleles of MAGE-A1 were present in
KWS-I, and the methylated and demethylated alleles of MAGE-A3
were present in MKN1, MKN7, MKN28, MKN45, MKN74, KATO-
III, and ECC10.
Expression of MAGE-A1 was confirmed in seven cell lines
(MKN1, MKN7, MKN28, MKN74, KATO-III, TSG11, and ECC12),
but not in the remaining three lines (MKN45, KWS-I, and ECC10),
and expression of MAGE-A3 was confirmed in all lines except
KWS-I (Figure 2). We have confirmed the methylated or
unmethylated status of each MAGE promoter in all the gastric
cancer cell lines by direct sequencing of MSP products (data not
shown). Thus, promoter methylation of MAGE-A1 and -A3 directly
correlates with their expression, except for MAGE-A1 in line
ECC10.
Demethylation of MAGE-A1 and -A3 in primary gastric
cancers and corresponding non-neoplastic gastric tissues
Demethylation of MAGE-A1 and -A3 was detected in 29% (25 out
of 84) and 66% (56 out of 84) of gastric cancer samples and in 0%
(0 out of 84) and 7% (6 out of 84) of their corresponding non-
neoplastic gastric tissues, respectively (Figure 3). Demethylation of
both MAGE-A1 and -A3 was detected in 26% (22 out of 84) of the
samples and of either of the genes in 44% (37 out of 84). In the
remaining samples (29%, 25 out of 84), both promoters remained
methylated.
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and clinicopathological parameters
Gastric cancer patients who exhibited demethylation of both the
MAGE-A1 and -A3 promoters (n¼22) were at a more advanced
clinical stage (P¼0.0035). and had a higher incidence of lymph
node metastasis (P¼0.0007) compared with those who did not
have demethylated MAGE-A1 and -A3 promoters (n¼25)
(Table 1). Furthermore, patients with demethylated MAGE-A1
and -A3 promoters tended to have a worse prognosis, although this
difference was not statistically significant by the log rank test
(P¼0.183) (Figure 4). Patients with demethylation of only one of
the two promoters exhibited biological features intermediate to
those of the other two groups.
Figure 1 Methylation-specific PCR of gastric cancer cell lines. (A)
Methylated-sequence-specific PCR of MAGE-A1;( B) Unmethylated-
sequence-specific PCR of MAGE-A1;( C) Methylated-sequence-specific
PCR of MAGE-A3;( D) Unmethylated-sequence-specific PCR of MAGE-A3;
P, positive control; DW, distilled water; SM, size marker. Methylated MAGE-
A1 is present in lanes 4 and 7 (A), and demethylated MAGE-A1 is present in
all lanes except lane 4 (B). Methylated MAGE-A3 is present in lanes 1–7
and 9 (C), and demethylated MAGE-A3 is present in all lanes except lane 7
(D). Lanes: 1, MKN1; 2, MKN7; 3, MKN28; 4, MKN45; 5, MKN74; 6,
KATO-III; 7, KWS-I; 8, TSG11; 9, ECC10; and 10, ECC12.
Figure 2 Reverse transcription–PCR of gastric cancer cell lines; (A)
RT–PCR of MAGE-A1;( B) RT–PCR of MAGE-3;( C) RT–PCR of b-actin;
SM, size marker. MAGE-A1 mRNA is not present in lanes 4, 7, or 9 (A).
MAGE-A3 mRNA is not present in lane 7 (B). b-actin serves as an internal
control (C). Lanes: 1, MKN1; 2, MKN7; 3, MKN28; 4, MKN45; 5, MKN74; 6,
KATO-III; 7, KWS-I; 8, TSG11; 9, ECC10; and 10, ECC12.
Figure 3 Methylation-specific PCR of primary gastric cancer specimens and their corresponding non-neoplastic gastric tissues; (A) methylated-sequence-
specific PCR of MAGE-A1 in gastric cancer specimens; (B) unmethylated-sequence-specific PCR of MAGE-A1 in gastric cancer specimens; (C) methylated-
sequence-specific PCR of MAGE-A1 in non-neoplastic gastric tissues; (D) unmethylated-sequence-specific PCR of MAGE-A1 in non-neoplastic gastric tissues;
(E) methylated-sequence-specific PCR of MAGE-A3 in gastric cancer specimens; (F) unmethylated-sequence-specific PCR of MAGE-A3 in gastric cancer
specimens; (G) methylated-sequence-specific PCR of MAGE-A3 in non-neoplastic gastric tissues; (H) unmethylated-sequence-specific PCR of MAGE-A3 in
non-neoplastic gastric tissues; P, positive control; DW, distilled water; SM, size marker. Methylated MAGE-A1 and -A3 is present in all lanes (A, C, E, and G).
In gastric cancer specimens, demethyled MAGE-A1 and -A3 are present in lanes 1, 6, and 7 of (B) and in lanes 5-8 of (F), respectively, whereas none of the
non-neoplastic gastric tissues exhibit demethylation of MAGE-A1 or -A3 (D and H). Lanes: 1, M244; 2, M245; 3, M246; 4, M248; 5, M251; 6, M254; 7, M256;
8, M257; and 9, M262.
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MAGE-A1 and -A3 encode tumour-specific antigens that are
recognised on melanoma cells by autologous cytolytic T lympho-
cytes (Van der Bruggen et al, 1991; Boon et al, 1994). These genes
are expressed in a significant proportion of tumours of various
histological types, but not in normal tissues, except for male germ
line cells and placenta (De Plaen et al, 1994; Takahashi et al, 1995).
Demethylation of promoter CpG islands in MAGE genes triggers
their expression in tumour cells, whereas they are not expressed in
cells in which they remain methylated (De Smet et al, 1996). The
function of the MAGE peptides are not known, although their
tumour-specific expression is clearly of great importance for
immunotherapy (Marchand et al, 1999; Nishiyama et al, 2001;
Sadanaga et al, 2001). The MAGE-A1 and -A3 peptides are
expressed in 67–73% of gastric cancer cell lines (Inoue et al,
1995a; Li et al, 1996). In agreement with these data, we have
demonstrated that MAGE-A1 and -A3 mRNA are expressed in 70
and 90% of gastric cancer cell lines, respectively. MAGE-A1 and -
A3 mRNA has also been reported to be expressed in approximately
40% of primary gastric cancers (Inoue et al, 1995a,b; Li et al,
1996). However, these previous studies did not verify the
methylation status of the MAGE-A1 and -A3 promoter CpG
islands. In the present study, we showed that the methylation
status of the MAGE-A1 and -A3 promoters almost directly
correlated with their expression status in gastric cancer cell lines.
Global DNA hypomethylation is thought to occur during the
early stages of tumour development in gastric and other tissues
(Goelz et al, 1985; Narayan et al, 1998; Lin et al, 2001; Bariol et al,
2003). Additionally, in pulmonary carcinogenesis, demethylation
of the promoter CpG islands of MAGE genes has been observed not
only in tumours but also in the adjacent non-neoplastic lung
tissues and bronchial epithelia from smokers (Jang et al, 2001).
Therefore, MAGE genes may be activated prior to malignant
transformation in the lung, possibly by global DNA hypomethyla-
tion (Tamura, 2002). However, we have demonstrated that MAGE
gene promoters are demethylated more frequently in gastric
cancers at advanced clinical stages. Furthermore, demethylation of
Table 1 Correlation of MAGE promoter methylation status and clinicopathological characteristics in gastric cancer patients
Promoter methylation status P-value
Not
altered
One demethylated
promoter
Two demethylated
promoters
Not altered
vs rest
Not altered vs two
demethylated promoters
Number of patients 25 37 22
Age (mean) (Years) 66.8 64.6 69.1 NS NS
Gender NS NS
M2 0 2 5 1 9
F 5 12 3
Unknown 0 0 0
Stage 0.002 0.0035
Early 15 11 4
Advanced 10 26 18
Unknown 0 0 0
Histological differentiation NS NS
Differentiated 16 24 12
Undifferentiated 9 13 10
Unknown 0 0 0
Location NS NS
Lower 8 15 10
Middle 10 15 5
Upper 5 4 6
Unknown 2 3 1
Lymph node metastasis 0.03 0.0007
Present 7 21 17
Absent 18 16 5
Unknown 0 0 0
NS¼not significant by Fisher’s exact probability test.
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Figure 4 Methylation status and survival curve for gastric cancer patients.
Patients in the ‘two demethylated promoter’ group tended to have a worse
prognosis than patients in the ‘not altered’ group (P¼0.183). Patients in
the ‘one demethylated promoter’ group exhibited an intermediate survival
time between the two.
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gastric cancer patients. In a separate study, we have confirmed that
demethylation of MAGE-A1 and -A3 was also very rare in various
organs obtained at autopsies, from various age groups (data not
shown). Therefore, we hypothesise that demethylation of MAGE
genes occurs during progressive stages of gastric carcinogenesis,
probably after global DNA hypomethylation. Promoter CpG
islands of several tumour suppressor and tumour-related
genes are frequently methylated in both neoplastic and non-
neoplastic gastric epithelia (Tamura, 2002; Waki et al, 2002).
Hypermethylation of different genes increases with age in different
organs (Waki et al, 2003). These results suggest that hypermethy-
lation of promoter CpG islands occurs very early in gastric
carcinogenesis, in contrast to demethylation of MAGE gene
promoters.
Several studies have analysed MAGE gene expression Inoue et al,
1995a,b; Cravo et al, 1996; Li et al, 1996; Sadanaga et al, 2001), but
none have evaluated the demethylation status of their promoters in
gastric cancer. Inoue et al (1995a,b) detected MAGE expression in
about 40% of primary gastric cancers, but failed to find any
significant correlation between MAGE expression and clinico-
pathological parameters (Inoue et al, 1995a,b). In the present
study, demethylation of either MAGE-A1 or -A3 was not
significantly correlated with clinicopathological parameters,
but demethylation of both genes significantly correlated with
advanced clinical stage and lymph node metastasis. Furthermore,
we have noticed that patients with tumours showing demethylation
of both MAGE-A1 and -A3 tend to have a worse prognosis,
although this difference was not statistically significant. In
contrast, hypermethylation of the hMLH1 gene promoter is a
marker of a better prognosis (Yamamoto et al, 1999). No
correlation has been observed between demethylation of the
MAGE genes and hypermethylation of hMLH1 or p16 (data not
shown).
In summary, demethylation of the MAGE-A1 and -A3 promoters
frequently occurs during progressive stages of gastric carcinogen-
esis and may be associated with aggressive biological behaviour of
gastric cancer.
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